Despite preventive guidelines, iatrogenic contrast-induced nephropathy (CIN) ranks third as a cause of hospital-acquired AKI, impacts significantly on morbidity and mortality, and is associated with longer stays in hospitals, with higher medical costs. [1] [2] [3] [4] The rates of CIN vary, depending on the study definitions employed and underlying risk factors, and range from 0.6% to 30% or higher among risk groups. [5] [6] [7] [8] CIN is also associated with increased duration of hospitalisation and early and late mortality. In-hospital mortality due to CIN ranges from 7% to 22%. [9] McCullough et al. [9] reported early mortality of 1.1% in controls, 7.1% in CIN patients, and 35% in CIN patients that required dialysis. Owing to increased comorbidities, hospitalised patients have increased risk for developing CIN compared with ambulatory patients .
The rates of CIN vary, depending on the study definitions employed and underlying risk factors, and range from 0.6% to 30% or higher among risk groups. [5] [6] [7] [8] CIN is also associated with increased duration of hospitalisation and early and late mortality. In-hospital mortality due to CIN ranges from 7% to 22%. [9] McCullough et al. [9] reported early mortality of 1.1% in controls, 7.1% in CIN patients, and 35% in CIN patients that required dialysis. Owing to increased comorbidities, hospitalised patients have increased risk for developing CIN compared with ambulatory patients . [10] Inflammation and endothelial dysfunction, together with reactive oxygen species (ROS), are implicated in the pathogenesis of CIN. [8] Iodinated contrast media directly injures the renal tubular epithelium by producing ROS radicals that cause intra-renal vasoconstriction leading to ischaemia and death of tubular cells. [8, 10, 11] Serum albumin is an important antioxidant that reduces the formation of oxygen free radicals and is important in expanding intravascular volume. [12, 13] However, the role of serum albumin in reducing the incidence of CIN remains unexplored.
Sub-Saharan Africa has a dearth of data on rates of CIN. This study investigated the rates of CIN together with the influence of serum albumin, albuminuria, age, haemoglobin, and glomerular filtration rate (GFR) levels on CIN and patient outcomes.
Methods

Study design, setting and population
This study was a prospective observational study conducted at Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa, from 1 July 2014 to 30 July 2015. Ethical approval was obtained from the human research ethics committee (HREC) of the University of the Witwatersrand and informed written consent was obtained from all patients. We consecutively recruited hospitalised patients undergoing computed tomography (CT) and angiography from the Divisions of Radiology and Cardiology, respectively. The following exclusion criteria were used: <18 years of age; evidence of pre-existing AKI (clinical or laboratory); end-stage renal disease (ESRD); renal replacement therapy (RRT); prior contrast media administration in the preceding 7 days; pregnancy; or incomplete data.
Study procedures
The study physician reviewed participants' medical records and examined the participants in order to determine pre-existing risk factors for CIN. The medical records were reviewed to determine patient duration of hospitalisation, dialysis requirements and mortality. Study phlebotomists collected blood samples prior to and post contrast media administration. Pre contrast, urine was collected and analysed for microalbuminuria using the Chemistrip Micral 30 immune assay test (Roche 11544039172). Serum creatinine was analysed using the Jaffe method (Siemens ADVIA 1200 chemistry July 2016, Vol. 106, No. 7 system) and estimated GFR (eGFR) was calculated using the four variable CKD-EPI equation. [14] Iopamidol (Jopamiron 370, Axim Pharmaceuticals, Italy), a low osmolar contrast agent, was used in all CT scan and angiography procedures.
Study outcome measures
The primary endpoint was the occurrence of CIN, defined as a serum creatinine increase of >25% from baseline or an absolute increase of 44 µmol/L assessed within 48 -72 hours post contrast media administration as per the 2011 updated European Society of Urogenital Radiology (ESUR) guidelines. [15] [16] [17] Several studies have used the ESUR definition.
The secondary endpoints were death and duration of hospitali sation obtained from patient records. The CIN group was reviewed for renal recovery and progression to chronic kidney disease (CKD) at 3 months following the contrast exposure.
Statistical analysis
Statistical analyses were performed using Stata version 13 software (Stata Inc., USA). Using conservative estimates for the prevalence of CIN, a minimum sample size of 323 was required to sufficiently power this study. Continuous variables are presented as means and standard deviations 
Results
Baseline characteristics
Participants' baseline characteristics are repor ted in Table 1 . After excluding 60 noneligible patients (Fig. 1) , 371 participants remained in the study; 74.9% were black, 18.9% white, 3.8% Indian and 2.4% of mixed race. Ages ranged from 18 to 92 years (mean (standard deviation) 49.3 (15.9)). The rate of CIN was 16.4% (61/371) when based on a 25% increase from baseline in serum creatinine and 4.6% when based on an absolute increase of >44 µmol/L. Baseline serum creatinine and GFR were not significantly different between the CIN and control groups; almost 97% had baseline GFR ≥60 mL/min/1.73 m 2 , while the remaining 3% had baseline GFR ranging from 42 to 59 mL/min/1.73 m 2 . Compared with the CIN-free group, CIN patients had significantly lower levels of baseline serum albumin and haemoglobin.
Independent predictors of CIN
After adjusting for all possible confounders, anaemia was found to be a predictor for CIN. Also, low serum albumin was positively associated with CIN development (Table 2) .
CIN and mortality
Both duration of hospitalisation and mortality were higher in the CIN group but only mortality was significantly increased (p<0.001) (Fig. 2) . None of the patients who developed CIN required dialysis. Nonsignificant variables that included cardiac disease, malignancy, contrast volume and baseline eGFR and albumin were excluded in the final model. In multivariable analysis CIN and anaemia were positive predictors for mortality (Table 3) .
Discussion
The present study demonstrated a rela tively high rate of CIN in hospitalised patients.
Assessed for eligibility, N=431
Study participants, n=371
Excluded, n= 60 Not meeting inclusion criteria, n=38 Missing lab data, n=22
Within 48 -72 hours CIN negative, n=310
Recovered AKI, n=36
CKD, n=5
In-hospital mortality, n=13
Survived, n=48
In-hospital mortality, n=20
Lost to follow-up, n=7 4 = not reachable 2 =declined 1 = died At 3 months Furthermore, the development of CIN resulted in increased mortality and highlighted the association of CIN with poorer clinical outcomes. Our study showed a 16.4% rate of CIN, which was slightly higher than reported in most recent studies. The reported incidence of CIN is variable, depending on the study definitions employed and underlying risk factors, and ranges from 5% to 30% overall. [5] [6] [7] [8] 18, 19] Recent observational studies have reported low rates of CIN among hospitalised patients. [20, 21] ShamsEddin Taher [21] observed a 11.5% rate of CIN in patients undergoing percutaneous intervention (PCI) while Selistre et al. [20] reported a 14% incidence of CIN in patients undergoing contrast CT administration in Brazil. A randomised controlled trial (RCT) in the USA found a 16.1% incidence of CIN in patients undergoing PCI. [22] The heterogeneous study population, variable comorbidities and non-standardised preventive prescriptions used by clinicians may explain the high rate of CIN in our study.
In this study, CIN patients had significantly lower levels of precontrast serum albumin compared with controls and showed a significant positive trend towards the development of CIN with serum albumin levels. Serum albumin is an important renoprotective, anti-inflammatory and antioxidant agent acting via several mechanisms; serum albumin binds non-ceruloplasmin copper and iron, which are important in the formation of ROS, and maintains renal perfusion by dilating renal vessels via its binding to nitrogen oxide, forming S-nitro-albumin. [12, [23] [24] [25] [26] However, during inflammation, albumin synthesis is reduced and activated neutrophils increase the levels of hypochlorous acid, which inactivates albumin. [12, 13, 23] Low serum albumin is probably a biomarker reflecting baseline susceptibility to acute or chronic inflammation or undernutrition. In two previous studies, Murat et al. [23] and Song et al. [24] found a positive association between low serum albumin and an increased risk for the development of CIN. A meta-analysis showed a positive association between decreased serum albumin and development of AKI, as well as increased morbidity and mortality. [27] The odds of developing AKI doubled with reduced serum albumin. [26] Lee et al. [28] reported twofold odds of developing postoperative AKI with decreased serum albumin.
Of interest in our study was the impact of baseline anaemia on patient outcomes. The rate of baseline anaemia was relatively high in our study population compared with controls, and was associated with development of CIN and a threefold mortality risk. Limited studies have explored the association of anaemia with CIN and patient outcomes. Li et al. [26] and Chong et al. [29] in observational studies reported a positive association between baseline anaemia and CIN . In these studies the presence of anaemia was associated with an almost twofold risk of developing CIN. [26, 29] In patients undergoing PCI, Mckechnie et al. [30] similarly reported baseline anaemia as an independent predictor for mortality. The increased risk of CIN in patients with anaemia and poorer clinical outcomes is multifactorial in aetiology; in the presence of anaemia, CIN-induced renal ischaemia and hypoxia are significantly worsened in the outer renal medulla amid already prevailing low oxygen tension, and oxygen affinity and demand are increased. [26, 31, 32] Anaemia also signifies underlying comorbidities; therefore it is a biomarker for severity of disease at the time of contrast media administration, and increased mortality risk. [26, 30] Age, baseline renal function (determined by eGFR) and prehydration were not associated with the prevention of CIN in our study. The positive association between CIN and age has been shown in the age group above 62 years. [11] An RCT found age above 75 years together with diabetes mellitus to be a predictor for CIN. [22] In younger type 2 diabetic patients undergoing PCI, Zaki et al. [25] reported age above 57 years to be a positive predictor for CIN. Our study population was relatively young, and fewer of our patients had multivessel disease compared with previous studies. Baseline eGFR level was insignificantly associated with CIN in our study cohort. Previous studies have shown decreased risk of developing CIN with eGFR >60 mL/ min/1.73 m 2 . [20] In an observational study, Weisbord et al. [33] found <1% incidence of CIN in patients with eGFR >45 -60 mL/ min/1.73 m 2 after contrast administration. In support of our study, Chong et al. [29] found insignificant association between normal renal status and CIN development. In a cohort study of 80% study participants with eGFR >60 mL/min/1.73 m 2 , Selistre et al. [20] also reported no association between baseline eGFR and risk for CIN. In our study cohort, 97% of study participants had normal baseline renal function based on eGFR, with the remaining having eGFR ranging from 42 to 59 mL/min/1.73 m 2 with no significant association with CIN.
Prehydration therapy was used in only 18% of patients in our study cohort compared with 70% seen in developed countries, [34] and prehydration showed no impact on reducing the incidence of CIN. It is possible that only the patients at highest risk for CIN received prehydration and this possibly obscured any beneficial effects. In previous studies, Selistre et al. [20] observed no association between fluid administration and CIN occurrence. Diogo et al. [35] reported a low rate of prehydration therapy in Brazil.
Similar to previous findings, our study demonstrated a higher mortality in the CIN group compared with controls, and CIN and anaemia were independent predictors of mortality. [36] Rihal et al., [37] in a retrospective registry review at the Mayo Clinic, reported in-hospital mortality rates of 22.0% and 1.4% in the CIN and controls groups, respectively, and CIN was positively associated with a 10-fold increased risk of death. Furthermore, cardiac disease was associated with a twofold increased risk of death. Sadeghi et al. [36, 38] in a multicentre study found that 30-day mortality was significantly higher among patients with CIN compared with controls (16.2% v. 1.2%; p<0.001). In-hospital mor- July 2016, Vol. 106, No. 7 tality due to CIN in the National Cardiovascular Registry in USA was reported as 9.1%. [39] Development of CIN also reflects underlying disease comorbidities at the time of contrast media administration. Despite increased mortality in the CIN group compared with controls, Sadeghi et al. [38] found underlying cardiac disease as a positive predictor for mortality. In other studies, age, cardiac disease and the requirement of dialysis were predictors for mortality in CIN participants. [36] In our study, among the 13 deaths in the CIN group, 7 had a diagnosis of malignancy; however, after adjusting for possible confounders, only CIN and anaemia (and not malignancy) were predictors of mortality.
The strength of our study is that it was a prospective cohort with a large sample size. However, it is limited by being a single-centre, non-interventional study conducted at a tertiary hospital. The study consisted of a heterogeneous population, and prevention guidelines for CIN were not standardised or uniformly implemented.
Conclusion
Our study highlights the high rates of CIN and associated poorer clinical outcomes. Caution should be used when administering iodinated contrast media to patients with hypoalbuminaemia and anaemia. To our knowledge, this is the first prospective study examining the risk and outcomes of CIN in sub-Saharan Africa. This study advocates that preventive treatment guidelines for CIN should be highlighted and standardised across various hospital departments.
